Most patients who have been offered colorectal cancer screening but turned it down are willing to undergo CT colonography as long as out-of-pocket fees are reasonable, according to a study.
Most patients who have been offered colorectal cancer screening but turned it down are willing to undergo CT colonography as long as out-of-pocket fees are reasonable, according to a study.
Of 68 patients who participated in the questionnaire, 83% said they would be willing to undergo CT colonography. However, 70% said they would not be willing to pay out-of-pocket fees if insurance did not cover the study. Among the 30% who said they would pay the fees, the average amount they were willing to pay (mean: $244, median: $150) was well below currently charged rates (AJR 2010;195:393-397).
Although the values may have been influenced by the study's small size, the values are consistent with the cost-effectiveness analysis by the Agency for Healthcare Research and Quality performed for CMS, the authors wrote. CMS found CT colonography could become a cost-effective screening strategy if its cost were $200 or less.
Photon-Counting Computed Tomography: Eleven Takeaways from a New Literature Review
May 27th 2025In a review of 155 studies, researchers examined the capabilities of photon-counting computed tomography (PCCT) for enhanced accuracy, tissue characterization, artifact reduction and reduced radiation dosing across thoracic, abdominal, and cardiothoracic imaging applications.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.